Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
Authors:
Open Access
- 21 November 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 10, 1217
Abstract
Background: The forefront treatment of Parkinson’s disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomena is especially pronounced in patients with Levodopa-induced dyskinesia (LID). Method: To study the effect of clinically-determined anti-parkinsonian medications, ten PD patients (5 with LID and 5 without LID) have been scanned with FDG-PET (a probe for glucose metabolism) and perfusion MRI (a probe for cerebral blood flow) both when they are ON and OFF medications. Patients additionally underwent resting state fMRI to detect changes in dopamine-mediated cortico-striatal connectivity. The degree of blood flow-glucose metabolism dissociation was quantified by comparing the FDG-PET and perfusion MRI. Results: A significant interaction effect (imaging modality × medication; blood flow-glucose metabolism dissociation) has been found in the putamen (p=0.023). Post-hoc analysis revealed that anti-parkinsonian medication consistently normalized the pathologically hyper-metabolic state of the putamen while mixed effects were observed in cerebral blood flow changes. This dissociation was especially predominant in patients with LID compared to the ones without. Unlike the prior study, this differentiation was not observed when cortico-striatal functional connectivity was assessed. Conclusion: We confirmed striatal neurovascular dissociation between FDG-PET and perfusion MRI in response to clinically determined anti-parkinsonian medication. We further proposed a novel analytical method to quantify the degree of dissociation in the putamen using only the ON condition scans, Putamen-to-thalamus Hyper-perfusion/hypo-metabolism Index (PHI), which may have a potential to be used as a biomarker for LID (correctly classifying 8 out 10 patients). For wider use of PHI, a larger validation study is warranted.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada
- Manitoba Medical Services Foundation
- Fondation Brain Canada
- King Saud University
This publication has 50 references indexed in Scilit:
- Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.2015
- Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humansBrain, 2015
- Effects of levodopa on regional cerebral metabolism and blood flowMovement Disorders, 2014
- PET demonstrates reduced dopamine transporter expression in PD with dyskinesiasNeurology, 2009
- Network modulation in the treatment of Parkinson's diseaseBrain, 2006
- Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic modelBrain, 2004
- Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.2004
- Metabolic correlates of levodopa response in Parkinson’s diseaseNeurology, 2001
- Neurogenic control of the cerebral microcirculation: is dopamine minding the store?Nature Neuroscience, 1998
- Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral dataMagnetic Resonance in Medicine, 1997